Cambridge, Mass.– Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapeutics, has promoted Dr. Pushkal Garg to the role of Executive Vice President and Chief Research and Development Officer. In this expanded leadership position, Dr. Garg will oversee a fully integrated R&D organization aimed at advancing Alnylam’s mission to develop transformative RNAi medicines across a broad spectrum of diseases.
The leadership transition comes as Alnylam moves into a new phase of growth following the commercial success of AMVUTTRA® for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The company now aims to accelerate development of its growing pipeline by fostering tighter collaboration between research and development teams.
“Pushkal’s strategic vision and operational expertise make him the ideal leader to guide our unified R&D organization,” said Dr. Yvonne Greenstreet, CEO of Alnylam. “As we continue to expand our clinical pipeline and pursue approvals for new RNAi therapeutics, his leadership will ensure we maintain our pace of innovation while maximizing our scientific impact for patients.”
Since joining Alnylam in 2014, Dr. Garg has played a key role in building the company’s development organization and driving successful clinical programs. Prior to Alnylam, he held leadership positions at Bristol-Myers Squibb and Millennium Pharmaceuticals. Dr. Garg holds a medical degree from the University of California, San Francisco, and has served on the faculty at Harvard Medical School and Brigham and Women’s Hospital.
In his new role, Dr. Garg emphasized Alnylam’s broader vision: “We’re only beginning to unlock the full potential of RNAi therapeutics. Our ambition is to deliver RNAi-based medicines to all major tissues in the body by 2030, which could open the door to treating many diseases that currently have limited or no effective therapies.”
Alnylam’s RNAi platform uses small interfering RNA (siRNA) to silence disease-causing genes before harmful proteins are produced, representing a breakthrough in genetic and precision medicine. The approach, which earned the 2006 Nobel Prize in Physiology or Medicine, continues to revolutionize drug development and holds promise for addressing a wide array of complex diseases.
With this leadership appointment, Alnylam reinforces its commitment to advancing RNAi science and expanding the frontiers of precision therapeutics for patients around the world.
